WO2003084507A3 - Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen - Google Patents

Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen Download PDF

Info

Publication number
WO2003084507A3
WO2003084507A3 PCT/DE2003/001068 DE0301068W WO03084507A3 WO 2003084507 A3 WO2003084507 A3 WO 2003084507A3 DE 0301068 W DE0301068 W DE 0301068W WO 03084507 A3 WO03084507 A3 WO 03084507A3
Authority
WO
WIPO (PCT)
Prior art keywords
liposomes
pulmonary administration
atomizable
active substances
substances
Prior art date
Application number
PCT/DE2003/001068
Other languages
English (en)
French (fr)
Other versions
WO2003084507A2 (de
Inventor
Thomas Schmehl
Tobias Gessler
Esther Waschkowitz
Original Assignee
Univ Giessen Justus Liebig
Thomas Schmehl
Tobias Gessler
Esther Waschkowitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Giessen Justus Liebig, Thomas Schmehl, Tobias Gessler, Esther Waschkowitz filed Critical Univ Giessen Justus Liebig
Priority to AU2003233921A priority Critical patent/AU2003233921A1/en
Priority to AT03727164T priority patent/ATE489940T1/de
Priority to DE50313292T priority patent/DE50313292D1/de
Priority to EP03727164A priority patent/EP1490026B1/de
Priority to US10/510,040 priority patent/US8652512B2/en
Publication of WO2003084507A2 publication Critical patent/WO2003084507A2/de
Publication of WO2003084507A3 publication Critical patent/WO2003084507A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die vorliegende Erfindung betrifft die Herstellung von spezi­fischen Liposomen zur pulmonalen Applikation von Arzneistof­fen. Die aus den Stoffen DPPC und Cholesterin im molaren Ver­hältnis von 7:3 bzw. 7:4 formulierten Liposomen werden durch nicht-toxische Zusätze wie Sphingomyelin, Dimyristoylphospha­tidylcholin und/oder Polyethylenglykol ergänzt, sind stabil gegenüber Vernebelung mit handelsüblichen Verneblern und wei­sen gleichzeitig eine verzögerte Freisetzungskinetik des Wirkstoffes auf.
PCT/DE2003/001068 2002-04-04 2003-04-01 Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen WO2003084507A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003233921A AU2003233921A1 (en) 2002-04-04 2003-04-01 Atomizable liposomes and their use for the pulmonary administration of active substances
AT03727164T ATE489940T1 (de) 2002-04-04 2003-04-01 Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen
DE50313292T DE50313292D1 (de) 2002-04-04 2003-04-01 Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen
EP03727164A EP1490026B1 (de) 2002-04-04 2003-04-01 Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen
US10/510,040 US8652512B2 (en) 2002-04-04 2003-04-04 Nebulized liposomes for the pulmonary application of drug compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10214983.6 2002-04-04
DE10214983A DE10214983A1 (de) 2002-04-04 2002-04-04 Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen

Publications (2)

Publication Number Publication Date
WO2003084507A2 WO2003084507A2 (de) 2003-10-16
WO2003084507A3 true WO2003084507A3 (de) 2004-02-12

Family

ID=28684760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/001068 WO2003084507A2 (de) 2002-04-04 2003-04-01 Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen

Country Status (7)

Country Link
US (1) US8652512B2 (de)
EP (1) EP1490026B1 (de)
AT (1) ATE489940T1 (de)
AU (1) AU2003233921A1 (de)
DE (2) DE10214983A1 (de)
ES (1) ES2356905T3 (de)
WO (1) WO2003084507A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100558351C (zh) 2003-05-22 2009-11-11 联合治疗公司 化合物和释放前列环素类似物的方法
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
EP1920765A1 (de) * 2006-11-07 2008-05-14 Medigene AG Single-Pass Verfahren zur Liposomherstellung
AR065865A1 (es) 2007-03-30 2009-07-08 Hirofumi Takeuchi Liposoma para la administracion pulmonar para controlar el suministro de la droga
DE102009031274A1 (de) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
ES2713852T3 (es) 2009-12-01 2019-05-24 Translate Bio Inc Derivado de esteroides para la administración de ARNm en enfermedades genéticas humanas
CN102892412B (zh) 2010-03-12 2015-09-30 博格制药有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
IL280771B2 (en) 2011-06-08 2024-03-01 Shire Human Genetic Therapies Preparations of lipid nanoparticles and methods for administration of mRNA
US10973763B2 (en) * 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
EP2859102A4 (de) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Nukleaseresistente polynukleotide und verwendungen davon
DK2970955T3 (en) 2013-03-14 2019-02-11 Translate Bio Inc METHODS FOR CLEANING MESSENGER RNA
KR20210122917A (ko) 2013-03-14 2021-10-12 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
EA034103B1 (ru) 2013-10-22 2019-12-27 Транслейт Био, Инк. СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
EP3134506B1 (de) 2014-04-25 2019-08-07 Translate Bio, Inc. Verfahren zur reinigung von messenger-rna
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
EP3624824A1 (de) 2017-05-16 2020-03-25 Translate Bio, Inc. Behandlung von zystischer fibrose durch verabreichung von codonoptimierter mrna, die cftr codiert
EP3784213B1 (de) 2018-04-23 2023-09-06 InspirMed Corp. Inhalierbare liposomale zubereitung mit verzögerter freisetzung zur behandlung von lungenerkrankungen
JP2021531252A (ja) * 2018-07-02 2021-11-18 アプタミアール セラピューティクス インコーポレイテッド ヒト脂肪細胞への治療薬の標的化送達
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361894A2 (de) * 1988-09-28 1990-04-04 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ladung und gesteuerte Abgabe von Molekülen zu und von Liposomen
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
WO2002003959A1 (en) * 2000-07-06 2002-01-17 The General Hospital Corporation Drug delivery formulations and targeting

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732914A (en) * 1978-02-13 1988-03-22 The Upjohn Company Prostacyclin analogs
JPH0768117B2 (ja) 1983-05-06 1995-07-26 ベスター・インコーポレイテツド 薬剤放出調整用小胞製剤
US5340587A (en) * 1985-05-22 1994-08-23 Liposome Technology, Inc. Liposome/bronchodilator method & System
EP0223831B1 (de) 1985-05-22 1992-07-15 Liposome Technology, Inc. Verfahren und system zum einatmen von liposomen
MX9203291A (es) * 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
SE8601457D0 (sv) * 1986-04-01 1986-04-01 Draco Ab Compositions of liposomes and b?712-receptor active substances for inhalation
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
WO1992002244A1 (en) * 1990-07-31 1992-02-20 The Liposome Company, Inc. Accumulation of amino acids and peptides into liposomes
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US6764693B1 (en) 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5783566A (en) 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
WO1998055104A1 (fr) * 1997-06-06 1998-12-10 Shionogi & Co., Ltd. Perfectionnement d'un systeme d'administration de medicament
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US20030059375A1 (en) 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
CA2457148A1 (en) 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
US20030232019A1 (en) 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
WO2003075977A2 (en) 2002-03-05 2003-09-18 Cleveland State University Agglomerated particles for aerosol drug delivery
EP1485068A2 (de) 2002-03-20 2004-12-15 Advanced Inhalation Research, Inc. hGH (MENSCHLICHES WACHSTUMSHORMON) FORMULIERUNGEN ZUR PULMONALEN VERABREICHUNG
AU2003279004B2 (en) 2002-09-28 2009-10-08 Massachusetts Institute Of Technology Influenza therapeutic
US7879351B2 (en) 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US20060141029A1 (en) 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
JP2007500229A (ja) 2003-05-20 2007-01-11 ジョンズ・ホプキンズ・ユニバーシティ 腫瘍の治療のためのカテコールブタンの投与のための方法と組成物
CN100558351C (zh) 2003-05-22 2009-11-11 联合治疗公司 化合物和释放前列环素类似物的方法
CA2806525C (en) 2004-07-21 2014-09-16 Animas Corporation Method and systems for providing an infusion device interface
WO2009070609A2 (en) 2007-11-27 2009-06-04 The Board Of Regents Of The University Of Texas System Therapeutic targeting of il-6 using sirna in neutral liposomes
WO2009127060A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2009129395A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361894A2 (de) * 1988-09-28 1990-04-04 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ladung und gesteuerte Abgabe von Molekülen zu und von Liposomen
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
WO2002003959A1 (en) * 2000-07-06 2002-01-17 The General Hospital Corporation Drug delivery formulations and targeting

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SINGH M ET AL: "Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 59, no. 1, 1 May 1999 (1999-05-01), pages 43 - 53, XP004166214, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
ES2356905T3 (es) 2011-04-14
AU2003233921A1 (en) 2003-10-20
DE10214983A1 (de) 2004-04-08
EP1490026A2 (de) 2004-12-29
US8652512B2 (en) 2014-02-18
EP1490026B1 (de) 2010-12-01
US20060002992A1 (en) 2006-01-05
ATE489940T1 (de) 2010-12-15
WO2003084507A2 (de) 2003-10-16
DE50313292D1 (de) 2011-01-13

Similar Documents

Publication Publication Date Title
WO2003084507A3 (de) Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
HUP0300188A3 (en) Carboxylic acid derivatives as ip antagonists, process for their preparation and pharmaceutical compositions containing them
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
AU2001278771A1 (en) Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient
CA2359813A1 (en) Nicotine mucosal spray
MY142029A (en) Phenoxyacetic acid derivatives
WO2001032632A3 (en) Pharmaceutically active 4-substituted pyrimidine derivatives
CA2468916A1 (en) A stable oxaliplatin solution formulation
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
WO2001096334A3 (en) Heteroarylalkanoic acids as integrin receptor antagonists
HUP0401963A3 (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2004033418A3 (en) Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
ZA9811796B (en) New tetracyclic analogues of camptothecins, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them.
WO2004026836A3 (en) 1-pyridin-4-yl-urea derivatives
CA2450093A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
WO2004078105A3 (fr) Composition de fondaparinux sodique de haute purete
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
HUP0303813A3 (en) Arylsulfonamides as antiviral agents, process for preparation of the compounds and pharmaceutical compositions containing them
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
WO2004017943A3 (en) Non-vesicular cationic lipid formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN ID JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003727164

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003727164

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006002992

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10510040

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10510040

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP